Skip to Main Content

Paper Details

A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Mol Cancer Ther
4
2022
Carfilzomib, Doxorubicin, MK-1775, MPNST, MPNST cell lines, MPNST-SP-01, MPNSTs, Malignant Peripheral Nerve Sheath Tumors, Malignant peripheral nerve sheath tumors, NF1, NVP-BGT226, Neurofibromatosis type 1, PDOX model, Panobinostat, TP53, TP53 mutated MPNST cell lines, Torin 2, athymic, athymic models, derived cell line, patient, patients, primary MPNST, soft-tissue sarcomas, tumor, tumors
Author NameAffiliation
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Rajarshi GuhaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
Margaret R WallaceUniversity of Florida College of Medicine
Karlyne M ReillyCenter for Cancer Research, National Cancer Institute
Karlyne M ReillyCenter for Cancer Research, National Cancer Institute
Jaishri O BlakeleyJohns Hopkins University School of Medicine
Marc FerrerDivision of Preclinical Innovation, National Center for Advancing Translational Sciences
  • 1 - 8

Datasets

Release 1.2